Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

Completed · Phase 1

Conditions studied: COVID-19

In brief

This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of IV Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who require supplemental oxygen.

Key facts

Study ID
NCT04456452
Run by
Ampio Pharmaceuticals. Inc.
People needed
10
Starts
2020-07-27
Expected to finish
2020-11-30
Last updated by the study team
2021-01-13

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.